Abby Swanson Kazley, PhD, Kit N. Simpson, DrPH, Annie Simpson, PhD, Edward Jauch, MD, Robert J. Adams, MD
Stroke remains a leading cause of disability and is the fourth leading cause of death in the United States.1,2 Approximately 780,000 strokes occur in the United States annually; in 2004, stroke accounted for 1 of every 16 deaths.3 The burden of stroke is especially high in South Carolina, which is central within the so-called Stroke Belt.4-7 The Stroke Belt is an 11-state region in the southeastern United States that has been characterized as having a particularly high incidence of stroke.
Stroking This South Carolina Model: Will It Play in Peoria?
A Value-Based Analysis of Hemodynamic Support Strategies for High-Risk Heart Failure Patients Undergoing a Percutaneous Coronary Intervention
David Gregory, MPA, Dennis J. Scotti, PhD, MBA, Gregory de Lissovoy, PhD, MPH, Igor Palacios, MD, Simon Dixon, MD, Brijeshwar Maini, MD, William O’Neill, MD
More than 1 in 3 American adults have at least one type of cardiovascular disease, which is the leading cause of death in the United States for men and women.1 The total annual burden of heart disease is estimated to be $312.6 billion in combined direct and indirect costs.1 In addition to an overall annual cost of more than $34 billion,2 heart failure is one of the main medical conditions necessitating acute hemodynamic support.
Careful Selection of Candidates for Percutaneous Ventricular Assist Device Is Crucial
Patricia Sacco, MPH, RPh, Gorana Capkun-Niggli, PhD, Xin Zhang, MS, Rosemary Jose, PhD, Michael F. Murphy, MD, PhD
Fragile X syndrome (FXS) is the most common form of inherited intellectual disability, with cognitive and behavioral impairments of varying degrees that are associated with distinct physical features.1 This neurodevelopmental disorder is caused by the silencing of a single X-linked gene, the fragile X mental retardation 1 gene, and hence manifests primarily in males.
Rarity, Disease Heterogeneity, and a Pathway for Estimating Economic Burden
Budget Impact Model: Epigenetic Assay Can Help Avoid Unnecessary Repeated Prostate Biopsies and Reduce Healthcare Spending
Wade Aubry, MD, Robert Lieberthal, PhD, Arnold Willis, MD, Grant Bagley, MD, Simon M. Willis III, MS, Andrew Layton, BA
Prostate cancer is the most frequently detected cancer in men, and 1 of 6 men will be diagnosed with prostate cancer during their lifetime based on Medicare enrollment data.1 In the United States, approximately 19 million men annually are screened by prostate-specific antigen (PSA) testing,2 resulting in approximately 4.7 million abnormal PSA test results (≥4.0 ng/mL)3 leading to approximately 1.3 million biopsy procedures.4 According to the National Cancer Institute, 241,740 men are diagnosed with prostate cancer annually, and 28,170 prostate
Molecular Epigenetic Tests Can Improve Clinical Outcomes While Reducing Healthcare Costs
The Opportunity for Health Plans to Improve Quality and Reduce Costs by Embracing Primary Care Medical Homes
The large and growing cost of healthcare, which amounted to 17.9% of the gross domestic product in 2011,1 will continue to be a burden for all payers in the US healthcare system, not only for states that are struggling to meet Medicaid costs and the federal government’s requirements, but also for private health plans that serve commercial, Medicare Advantage, and Medicaid beneficiaries.2,3 Costs will continue to grow as millions more people become newly insured because of the Patient Protection and Affordable Care Act (ACA).
Enhancing Health Outcomes and Quality of Care with the Medical Home Model in Primary Care
Current and Future Use of HEOR Data in Healthcare Decision-Making in the United States and in Emerging Markets
Anke-Peggy Holtorf, PhD, MBA, Diana Brixner, RPh, PhD, Brandon Bellows, PharmD, Abdulkadir Keskinaslan, MD, MBA, MPH, Joseph Dye, RPh, PhD, Gary Oderda, PharmD, MPH
With increasing access and utilization of healthcare, resources become more restricted, and prioritization in healthcare becomes unavoidable. Health economics and outcomes research (HEOR) is a discipline that is used to complement traditional clinical development information (ie, efficacy, safety, quality) to guide decision makers regarding patient access to specific drugs and services. HEOR has advanced considerably in methodology and in quantity over the past several decades.
Health Economics and Outcomes Research Data Key in Coverage Decisions of New Medications
Hematologic Complications, Healthcare Utilization, and Costs in Commercially Insured Patients with Myelodysplastic Syndrome Receiving Supportive Care
Annette Powers, PharmD, MBA, Claudio Faria, PharmD, MPH, Michael S. Broder, MD, MSHS, Eunice Chang, PhD, Dasha Cherepanov, PhD, Jeffrey A. Bourret, PharmD, MS, BCPS, FASHP
Myelodysplastic syndrome (MDS) encompasses a heterogeneous group of clonal disorders of hematopoiesis and is characterized by dysplastic morphology of marrow and blood cells, ineffective hematopoiesis, and peripheral blood cytopenias.1,2 Most patients with MDS experience progressive worsening of blood cytopenias, with an increasing need for transfusion.2 These patients also have an increasing number of potentially fatal infections and hemorrhagic complications.2 The more advanced and severe the MDS is, the greater the risk that the disease will progress to a
Reconsidering the Management of Younger Patients with Myelodysplastic Syndrome
Medical Care Costs and Hospitalization in Patients with Bipolar Disorder Treated with Atypical Antipsychotics
Joette Gdovin Bergeson, PhD, MPA, Iftekhar Kalsekar, PhD, Yonghua Jing, PhD, Min You, MS, Robert A. Forbes, PhD, Tony Hebden, PhD
Bipolar disorder is a chronic, recurring disorder associated with frequent episodes of mania and depression.
The Potential Value of Benefit Design and Medication Selection for a Total-Cost-of-Care Strategy in Bipolar Disease
The eighteenth-century essayist and satirist Jonathan Swift made the observation that “vision is the art of seeing things invisible.” So, too, is “the art of seeing things invisible” a key for the ongoing sustainability of health information exchange (HIE). HIEs have long been theorized to provide a number of tangible benefits.
Significant Potential for Health Information Exchange in Enhancing Quality of Care and Reducing Hospital Admissions in the United States
Curbing the Costly Trend: Exploring the Need for a Progressive Approach to the Management of Specialty Pharmaceuticals Under the Medical Benefit
Page 6 of 11
Results 51 - 60 of 106
Results 51 - 60 of 106